A new divergent asymmetric synthesis of (+)- and (-)-ethosuximides and their anticonvulsant activities

Heterocycles

Volumn 50, Issue 2, 1999, Pages 833-841

  Katoh, Takahiro ^a   Nishide, Kiyoharu ^a   Node, Manabu ^a   Ogura, Hiroo ^b  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKENE; ENAMINE; ETHOSUXIMIDE; GAMMA BUTYROLACTONE; LACTONE; PROLINE;

ANTICONVULSANT ACTIVITY; ARTICLE; CHEMICAL REACTION; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 0033117728     PISSN: 03855414     EISSN: None     Source Type: Journal    
DOI: 10.3987/com-98-s(h)78     Document Type: Article

References (28)

1. For asymmetric nitroolefination see: a) K. Nishide, R. Kurosaki, K. Hosomi, H. Imazato, T. Inoue, M. Node, T. Ohmori, and K. Fuji, Tetrahedron, 1995, 51, 10857.
2. b) M. Node, R. Kurosaki, K. Hosomi, T. Inoue, K. Nishide, T. Ohmori, and K. Fuji, Tetrahedron Lett., 1995, 36, 99.
3. c) K. Fuji, T. Kawabata, T. Ohmori, and M. Node, Synlett, 1995, 367.
4. d) K. Fuji, T. Kawabata, Y. Naniwa, T. Ohmori, and M. Node, Chem. Pharm. Bull., 1994, 42, 999.
5. e) K. Fuji and M. Node, Synlett, 1991, 603.
6. f) M. Node and K. Fuji, J. Syn. Org. Chem. Jpn., 1990, 48, 389.
7. g) K. Fuji, M. Node, H. Nagasawa, Y. Naniwa, T. Taga, K. Machida, and G. Snatzke, J. Am. Chem. Soc., 1989, 111, 7921.
8. h) M. Node, H. Nagasawa, Y. Naniwa, and K. Fuji, Synthesis, 1987, 729.
9. i) K. Fuji, M. Node, H. Nagasawa, Y. Naniwa, and S. Terada, J. Am. Chem. Soc., 1986, 108, 3855.
10. For application of asymmetric nitroolefination see: a) M. Node, H. Nagasawa, and K. Fuji, J. Org. Chem., 1990, 55, 517.
11. b) M. Node, H. Nagasawa, and K. Fuji, J. Am. Chem. Soc., 1987, 109, 7901.
12. c) M. Node, X.-J. Hao, K. Nishide, and K. Fuji, Chem. Pharm. Bull., 1996, 44, 715.
13. d) M. Node, X.-J. Hao, and K. Fuji, Chem. Lett., 1991, 57.
14. e) M. Node, A. Itoh, Y. Masaki, and K. Fuji, Heterocycles, 1991, 32, 1705.
15. f) X.-J. Hao, M. Node, and K. Fuji, J. Chem. Soc., Perkin Trans. I, 1992, 1505.
16. g) K. Fuji, S.-Z. Zheng, M. Node, and X.-J. Hao, Chem. Pharm. Bull., 1991, 39, 202.
17. h) M. Node, X.-J. Hao, H. Nagasawa, and K. Fuji, Tetrahedron Lett., 1989, 30, 4141.
18. K. Nishide, T. Katoh, H. Imazato, and M. Node, Heterocycles, 1998, 47, 839.
19. For synthesis of (±)-ethosuximide see: a) P. A. S. Smith and J. P. Horwitz, J. Am. Chem. Soc., 1949, 71, 3418.
20. b) S. S. G. Sircar, J. Chem. Soc., 1927, 1252.
21. c) H. Ishibashi, T. Nakaharu, M. Nishimura, A. Nishikawa, C. Kameoka, and M. Ikeda, Tetrahedron, 1995, 51, 2929. For synthesis of (+)-and (-)-ethosuximides:
22. d) J. Knabe and W. Koch, Arch. Pharm., 1972, 305, 757.
23. e) J. Knabe and J. Plisch, Tetrahedron Lett., 1973, 745.
24. a) L. Sorel, Acta Neurol. Psychiat. Belg., 1960, 60, 551.
25. b) T. Hirai, N. Ando, T. Naoi, R. Inoue, and H. Watanabe, Seishin Igaku, 1965, 7, 142.
26. It is considered that the enhancement of optical purity (91 → 98% ee) occurred when acids (8, 9) and (S)-ethosuximide crystallized.
27. T. R. Kelly, H. M. Dali, and W.-G. Tsang, Tetrahedron Lett., 1977, 3859.
28. J. F. Reinhard and J. F. Reinhard, Jr., 'Anticonvulsants: Experimental Evaluation of Anticonvulsants' ed. by J. Aavida, Academic Press, Inc., New York, 1977, pp. 55-111.